Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.24.2.u1
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Operating Expenses:        
Research and development $ 1,784,000 $ 2,095,000 $ 2,561,000 $ 3,745,000
Selling, general and administrative (including $120,000 and $398,000 from stock compensation granted to officers, directors, and employees during the three months ended June 30, 2024 and 2023, respectively, and $222,000 and $905,000 for the six months ended June 30, 2024 and 2023, respectively) 2,122,000 1,526,000 4,436,000 3,541,000
Loss from Operations (3,906,000) (3,621,000) (6,997,000) (7,286,000)
Other Income (Expense)        
Interest income 105,000 220,000 247,000 384,000
Interest expense (1,000) (213,000)
Change in fair value of warrant liability 117,000 1,387,000 775,000 4,311,000
Gain on extinguishment of debt 14,000 547,000
Unrealized gain (loss) on marketable securities 1,000 9,000 (1,000) 38,000
Other (27,000)
Total Other Income 196,000 1,629,000 1,021,000 5,067,000
Net Loss $ (3,710,000) $ (1,992,000) $ (5,976,000) $ (2,219,000)
Net Loss Per Share - Basic $ (2.17) $ (1.49) $ (3.86) $ (1.68)
Net Loss Per Share - Diluted $ (2.17) $ (1.49) $ (3.86) $ (1.68)
Weighted average common shares outstanding - basic 1,711,955 1,339,087 1,546,294 1,321,069
Weighted average common shares outstanding - diluted 1,711,955 1,339,087 1,546,294 1,321,069